CDCP1 and ovarian serous adenocarcinoma: In EOC, increased CDCP1 expression has been reported in significant proportions of tumors compared with normal fallopian tube or ovary, including in 77% of high grade serous ovarian cancer cases 10 and 90% of clear cell ovarian cancer cases 11, indicating that a large proportion of EOC cases may benefit from CDCP1 targeted agents for imaging or treatment.